Trade Summary

3 months ago, Hopman Mark, serving as Chief Commercial Officer at Beta Bionics, Inc. (BBNX), sold 2,917 shares at $30.27 per share, for a total transaction value of $88,304.00. Following this transaction, Hopman Mark now holds 136,216 shares of BBNX.

This sale represents a 2.00% decrease in Hopman Mark's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, December 2, 2025 and publicly disclosed via SEC Form 4 filing on Monday, March 16, 2026, 104 days after the trade was made.

Beta Bionics, Inc. operates in the HEALTHCARE sector, specifically within the MEDICAL DEVICES industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.